Publications by authors named "Marie Indrova"

Claim this Profile
T
The role of immune cell subpopulations in the growth and rejection of TC-1/A9 tumors in novel mouse strains differing in the H2-D haplotype and NKC domain.
Marie Indrová, Joanna Rossowska, Elzbieta Pajtasz-Piasecka, Romana Mikyšková, Jan Richter

Oncol Lett· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice.
Romana Mikyskova, Marie Indrova, Ivan Stepanek, Ivan Kanchev, Jana Bieblova

Oncoimmunology· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance of novel mouse strains different in MHC class I and the NKC domain to the development of experimental tumors.
Anna Fišerová, Jan Richter, Katarína Čapková, Jana Bieblová, Romana Mikyšková

Int J Oncol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor growth accelerated by chemotherapy-induced senescent cells is suppressed by treatment with IL-12 producing cellular vaccines.
Jana Simova, Olena Sapega, Terezie Imrichova, Ivan Stepanek, Lenka Kyjacova, Marie Indrova

Oncotarget· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy.
Romana Mikyšková, Ivan Štěpánek, Marie Indrová, Jana Bieblová, Jana Šímová

Int J Oncol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epigenetic regulations in the IFNγ signalling pathway: IFNγ-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes.
Veronika Vlková, Ivan Štěpánek, Veronika Hrušková, Filip Šenigl, Veronika Mayerová

Oncotarget· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA demethylating agent 5-azacytidine inhibits myeloid-derived suppressor cells induced by tumor growth and cyclophosphamide treatment.
Romana Mikyšková, Marie Indrová, Veronika Vlková, Jana Bieblová, Jana Šímová

J Leukoc Biol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model.
Rodney A Rosalia, Ivan Štěpánek, Veronika Polláková, Jana Šímová, Jana Bieblová

Immunobiology· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors.
Romana Mikyšková, Marie Indrová, Veronika Polláková, Jana Bieblová, Jana Símová

J Immunother· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine.
Romana Mikyšková, Marie Indrová, Jana Símová, Jana Bieblová, Jan Bubeník

Oncol Rep· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours.
Marie Indrová, Jana Símová, Jana Bieblová, Jan Bubeník, Milan Reinis

Oncol Rep· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy for minimal residual tumor disease: beta-galactosylceramide inhibits the growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy.
Jana Símová, Marie Indrová, Jana Bieblová, Romana Mikysková, Jan Bubeník

Int J Cancer· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines.
Milan Reinis, Ivan Stepanek, Jana Simova, Jana Bieblova, Hana Pribylova, Marie Indrova

Int J Oncol· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dendritic cell-based vaccines for the therapy of experimental tumors.
Elzbieta Pajtasz-Piasecka, Marie Indrová

Immunotherapy· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy.
Marie Indrová, Jana Bieblová, Joana Rossowska, Piotr Kuropka, Elzbieta Pajtasz-Piasecka

Int J Oncol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours.
Jasper Manning, Marie Indrova, Barbora Lubyova, Hana Pribylova, Jana Bieblova

Immunology· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours: induction of immune responses, cytokine production and kinetics of immune cell subsets.
Marie Indrová, Jana Bieblová, Jan Bubeník, Milan Reinis

Int J Oncol· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours.
Milan Reinis, Jana Símová, Marie Indrová, Jana Bieblová, Jan Bubeník

Int J Oncol· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunization with MHC class I-negative but not -positive HPV16-associated tumour cells inhibits growth of MHC class I-negative tumours.
Milan Reinis, Jana Símová, Marie Indrová, Jana Bieblová, Hana Pribylová

Int J Oncol· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differences in pathogenicity among strains of the same or different avian leukosis virus subgroups.
Dana Průková, Zdenka Vernerová, Tomás Pilcík, Volodymir Stepanets, Marie Indrová

Avian Pathol· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours.
Marie Indrová, Jana Bieblová, Tána Jandlová, Vladimír Vonka, Elzbieta Pajtasz-Piasecka

Int J Oncol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
Romana Mikysková, Jan Bubeník, Vladimír Vonka, Michal Smahel, Marie Indrova

Int J Oncol· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines.
Milan Reinis, Marie Indrová, Luis Mendoza, Romana Mikysková, Jana Bieblová

Int J Oncol· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.
Romana Mikysková, Marie Indrová, Jana Símová, Tána Jandlová, Jana Bieblová

Int J Oncol· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Marie Indrová, Jan Bubeník, Romana Mikysková, Luis Mendoza, Jana Símová

Int J Oncol· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis